USPTO serial 99477945
OMNIULTRA
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- HOLLAND, JAMI ELENA
- Law office
- TMO LAW OFFICE 122
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OMNIULTRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Francis P. Cislak
Francis P. Cislak Barnes & Thornburg LLP11 South Meridian StreetIndianapolis, IN 46204-3535United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | synthesized peptides for scientific and research use; for research purposes, excluding those for medical or veterinary use; proteins and synthesized peptides used in the research, product development, and manufacture of pharmaceuticals; chemical reagents for use in evaluating genetic material, namely, the detection, measurement and identification of genetic materials and their compounds, excluding those for medical and veterinary use; biological tissue, namely, animal tissue for use in scientific and medical research; cells for scientific and research use; stem cells for scientific and research use; antibodies for use in further scientific and medical research | ACTIVE | — |
| 005 | synthesized peptides for medical use, namely, for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders; biological reagents for medical use; chemical reagents for medical use, namely, for the detection, measurement and identification of genetic materials; biological tissue cultures, namely, animal tissue cultures for medical purposes; antibodies for medical; radiopharmaceutical compositions for medical diagnostic or therapeutic use, namely, diagnostic radiopharmaceutical preparations and radiopharmaceuticals for the diagnosis or treatment of cancer, cardiovascular disease, lung disease, thyroid disease, bone disease, brain disease, and bodily tissue disease; synthesized peptides for use in drug discovery of pharmaceuticals for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders; chemical preparations for use in drug discovery for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders; pharmaceutical preparations for use in the treatment of medical conditions, namely, suppressing tumors; diagnostic preparations for medical purposes; pharmaceutical preparations in the nature of synthesized peptides for use in drug discovery and pharmaceuticals for the treatment of for medical purposes; synthesized proteins and chemical preparations for use in drug discovery and pharmaceuticals for the treatment of viral diseases, respiratory diseases, autoimmune diseases, immune diseases, inflammatory diseases, dermatological diseases, cancer, endocrine diseases, heptalogical diseases, pain, infectious diseases, metabolic diseases and disorders | ACTIVE | — |
| 040 | manufacture of synthetic peptides and antibodies to the order and specification of others; peptide and antibody synthesis for others, namely, manufacture of synthetic peptides and antibodies to the order and specification of others | ACTIVE | — |
| 042 | Scientific research services in the field of the analysis and synthesis of peptides and antibodies; Scientific research services in the field of the analysis and synthesis of proteins; quality control of peptides and antibodies used in drug development; advice on quality control of peptides and antibodies used in drug development; scientific research and development; scientific research and development in the field of immunization and antibody screening | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 30, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 30, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 30, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 30, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 4, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 4, 2025 | NWAP | NEW APPLICATION ENTERED | — |